Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
QuidelOrtho Corporation is a U.S.-based medical diagnostics company operating within the in vitro diagnostics (IVD) industry. The company develops, manufactures, and commercializes diagnostic testing solutions used in hospitals, clinical laboratories, blood banks, physician offices, and other healthcare settings. Its core offerings span immunoassay, molecular diagnostics, clinical chemistry, and transfusion medicine, serving both acute and routine diagnostic needs.
The company was formed in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics, combining Quidel’s strengths in rapid diagnostic and point-of-care testing with Ortho’s established laboratory diagnostics and transfusion medicine franchises. This merger created a diversified diagnostics platform with a broad installed base, recurring consumables revenue, and global reach. The company is positioned as a comprehensive diagnostics provider with scale across decentralized and centralized testing environments.
Business Operations
QuidelOrtho generates revenue primarily through the sale of diagnostic instruments, test consumables, reagents, and related services. Its operations are organized across three major business segments: Labs, Transfusion Medicine, and Point of Care. The Labs segment includes clinical chemistry, immunoassay, and molecular diagnostic systems used in hospital and reference laboratories, while Transfusion Medicine focuses on blood typing, screening, and compatibility testing for blood banks. The Point of Care segment provides rapid diagnostic tests for infectious diseases and other conditions, often used in near-patient or decentralized settings.
The company operates manufacturing, research, and commercial activities across domestic and international markets. It controls proprietary diagnostic platforms, assay menus, and automation technologies, supported by a global sales and service organization. Key operating subsidiaries include Ortho Clinical Diagnostics and Quidel, which continue to represent distinct product portfolios within the broader corporate structure.
Strategic Position & Investments
QuidelOrtho’s strategic direction emphasizes portfolio integration following the merger, expansion of its recurring consumables revenue base, and continued innovation across both laboratory-based and point-of-care diagnostics. Growth initiatives include menu expansion on existing diagnostic platforms, increased automation in transfusion medicine, and operational efficiency improvements across manufacturing and supply chains.
The company has made significant investments in assay development, diagnostic instrumentation, and digital connectivity to enhance laboratory workflow and clinical decision-making. While the merger itself represents the most significant recent transaction, QuidelOrtho continues to evaluate targeted investments in emerging diagnostic technologies, particularly in infectious disease testing and laboratory automation, where demand is supported by long-term healthcare utilization trends.
Geographic Footprint
QuidelOrtho is headquartered in the United States and operates globally across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The company maintains manufacturing and R&D facilities in multiple regions, supporting localized production and regulatory compliance for international markets.
Its products are distributed to hospitals, laboratories, and healthcare providers in more than 100 countries, with particularly strong market positions in the United States, Western Europe, and Japan. International operations contribute a substantial portion of total revenue and play a critical role in the company’s long-term growth strategy and diversification.
Leadership & Governance
QuidelOrtho is led by an executive team with experience across diagnostics, healthcare manufacturing, and global operations. The leadership emphasizes operational discipline, innovation in diagnostic science, and leveraging the combined capabilities of its legacy organizations to deliver integrated diagnostic solutions.
Key executives include:
- Douglas C. Bryant – President and Chief Executive Officer
- Sanjay J. Patel – Chief Financial Officer
- Beth A. Ricci – Chief Human Resources Officer
- Jennifer K. Zinn – Chief Legal Officer and Corporate Secretary
- Naresh R. Mahajan – Chief Operating Officer
The company is governed by a board of directors overseeing strategy, risk management, and corporate governance, with a focus on long-term value creation, regulatory compliance, and ethical business practices.